Central Serous Chorioretinopathy: Causes, Treatment, and Recovery
Understanding Central Serous Chorioretinopathy
The retina sits on top of a layer of support cells called the retinal pigment epithelium, or RPE. Beneath the RPE is the choroid, a tissue layer rich in blood vessels that supplies oxygen and nutrients to the retina. In CSCR, the choroidal blood vessels become overly permeable, meaning they leak more fluid than normal. At the same time, the RPE fails to properly pump this excess fluid away from the retina.
When the RPE cannot keep up with the leaking fluid, a pocket of liquid collects under the retina. This creates a small, blister-like detachment right at the macula, the central part of the retina responsible for sharp, detailed vision. The fluid pushes the retina slightly out of position, which is why people with CSCR notice blurred or distorted central vision.
Research has shown that the choroid in patients with CSCR is often thicker than normal. This thickening is linked to increased pressure and leakage from choroidal blood vessels. Scientists believe that mineralocorticoid receptors, which are proteins found in retinal cells, may play a role. When these receptors are overactivated, they can cause choroidal blood vessels to dilate and leak, leading to the fluid buildup that defines CSCR.
CSCR is generally classified into two forms. Acute CSCR involves a single episode of fluid buildup that typically resolves on its own within two to three months. Most people with acute CSCR recover good vision, though it may not return to exactly what it was before the episode.
Chronic CSCR occurs when the fluid persists for more than three to four months or keeps coming back over time. Chronic cases carry a higher risk of permanent damage to the retina and RPE. The Central Serous Chorioretinopathy International Group has also introduced a classification system that divides CSCR into simple and complex subtypes based on imaging findings, helping retina specialists tailor their approach to treatment.
Who Is Affected and Risk Factors
CSCR primarily affects adults between the ages of 30 and 50. Men are significantly more likely to develop the condition than women. Population studies have found an annual incidence rate of approximately 9.5 per 100,000 in men compared with 1.6 per 100,000 in women, with the median age at diagnosis being 35 to 39 years for men and 40 to 44 years for women (Kitzmann et al., American Journal of Ophthalmology, 2008). A large United States database study from 2015 to 2022 found that male eyes made up 71.8 percent of all CSCR cases (Retina, 2024). Overall, CSCR occurs roughly six times more commonly in men than in women (Kitzmann et al., American Journal of Ophthalmology, 2008).
One of the strongest and most well-established risk factors for CSCR is corticosteroid use. This includes corticosteroids taken by mouth, inhaled for asthma, applied to the skin as creams, or injected into joints. Even over-the-counter nasal allergy sprays that contain corticosteroids can increase the risk. If a person is diagnosed with CSCR, a retina specialist will typically ask about all forms of corticosteroid exposure and may recommend stopping or reducing these medications when it is safe to do so.
Psychological stress is a well-known trigger for CSCR. During periods of high stress, the body produces natural corticosteroids such as cortisol, which may contribute to the fluid leakage in the choroid. People described as having type A behavior patterns, characterized by high levels of competitiveness, urgency, and drive, appear to be at higher risk for developing CSCR. Stress management techniques may play a supportive role in reducing recurrence.
Several additional risk factors have been linked to CSCR. These include:
- Pregnancy, likely due to elevated natural corticosteroid levels
- Endogenous Cushing syndrome, a condition in which the body produces too much cortisol
- Helicobacter pylori infection, a bacterial stomach infection
- Autoimmune diseases
- Sleep disturbances, including insomnia and obstructive sleep apnea
- Family history of CSCR, with about half of patients having at least one relative with findings of the disease on retinal examination
Signs and Symptoms
CSCR typically affects one eye at a time, though it can occur in both eyes. The most common symptom is blurred central vision, as if looking through a smudge or a light haze. Many patients also experience metamorphopsia, which is distortion of straight lines or shapes. Objects may appear bent, wavy, or uneven when viewed with the affected eye.
Some people with CSCR notice micropsia, a condition where objects look smaller than they actually are. Colors may appear washed out or slightly different in the affected eye compared with the other eye. Some patients describe a dim spot or relative scotoma (a partial blind spot) in the center of their vision. These symptoms can be subtle and may be noticed only when covering the unaffected eye.
While CSCR itself is not typically a medical emergency, some symptoms can overlap with more serious retinal conditions such as retinal detachment. If a person experiences sudden vision loss, a dark curtain or shadow spreading across their vision, or a sudden increase in floaters accompanied by flashes of light, they should see a retina specialist or go to the emergency room immediately. These could indicate a different and more urgent retinal problem.
Diagnosis and Testing
A retina specialist will begin with a thorough eye examination, including a dilated fundus exam. During this exam, eye drops widen the pupil so the specialist can view the retina in detail. In many CSCR cases, the specialist can see a dome-shaped area of fluid under the macula. However, imaging tests are needed to confirm the diagnosis and determine the extent of the condition.
Optical coherence tomography, commonly known as OCT, is the primary imaging tool for diagnosing CSCR. OCT uses light waves to create detailed cross-sectional images of the retina. It clearly shows the pocket of fluid beneath the retina and can measure how much fluid is present. OCT is also used to monitor the condition over time and to assess whether the fluid is resolving or worsening.
Fluorescein angiography involves injecting a yellow dye into a vein in the arm. As the dye circulates through the blood vessels in the eye, a special camera captures images of the retinal and choroidal circulation. In CSCR, fluorescein angiography often reveals a characteristic pattern: a single point of dye leakage from the RPE, sometimes described as looking like a smokestack or an inkblot spreading outward. This test helps pinpoint the exact location of the leak.
Indocyanine green angiography, or ICG angiography, uses a different dye that is better at imaging the choroidal blood vessels. This test is especially useful for evaluating the extent of choroidal thickening and hyperpermeability, which are hallmarks of CSCR. Some retina specialists also use OCT angiography, a noninvasive imaging technique that can map blood flow in the retina and choroid without the need for dye injection. These imaging tools together help the specialist classify the type and severity of CSCR.
Treatment Options
For most cases of acute CSCR, the standard initial approach is careful observation. The majority of acute episodes resolve on their own within two to three months as the RPE regains its ability to pump fluid away from the retina. During this period, a retina specialist will schedule follow-up visits and OCT scans to monitor the fluid. The specialist may also recommend stopping any corticosteroid medications and addressing modifiable risk factors such as stress and sleep problems.
For chronic CSCR or cases that do not resolve on their own, half-dose photodynamic therapy, or PDT, is one of the most effective treatments available. During PDT, a light-sensitive drug called verteporfin is injected into a vein. A low-energy laser is then aimed at the affected area of the choroid, activating the drug and sealing the leaky blood vessels. The treatment uses half the standard drug dose to reduce the risk of side effects while remaining effective.
The SPECTRA trial, a landmark clinical study published in 2022, established that half-dose PDT is superior to oral eplerenone (a medication that blocks mineralocorticoid receptors). In that trial, 78 percent of patients treated with half-dose PDT achieved complete resolution of subretinal fluid at three months, compared with 17 percent of patients taking eplerenone (SPECTRA Trial, JAMA Ophthalmology, 2022). At 12 months, 89.6 percent of PDT-treated patients had complete fluid resolution.
Focal laser photocoagulation is an older treatment that uses thermal laser energy to seal the specific point where the RPE is leaking. This option may be considered when the leak is located away from the center of the macula, as applying laser directly to the fovea (the very center of the macula) could damage central vision. Focal laser can speed up fluid resolution but is used selectively based on the location of the leakage point.
Some retina specialists may consider oral medications for chronic CSCR. Eplerenone, a mineralocorticoid receptor antagonist, was studied as a potential treatment. However, the VICI trial, published in 2020, found that eplerenone showed no significant benefit over placebo in patients with chronic CSCR lasting more than four months (VICI Trial, The Lancet, 2020). Despite this, some specialists may still use eplerenone or a related drug called spironolactone in certain clinical situations, though the evidence for their effectiveness remains limited.
Anti-VEGF (anti-vascular endothelial growth factor) injections are not a standard treatment for typical CSCR. However, some patients with chronic CSCR develop choroidal neovascularization, a complication where abnormal new blood vessels grow under the retina. In these cases, anti-VEGF injections such as Avastin (bevacizumab), which is used off-label for eye conditions, or other anti-VEGF agents may be recommended to block the growth and leakage of these abnormal vessels. A retina specialist will determine whether this complication is present using imaging tests.
What to Expect
Most people with a first episode of acute CSCR can expect the fluid to resolve within two to three months. As the fluid absorbs, vision gradually improves. However, some patients notice that their vision does not return completely to its previous level. Subtle differences in contrast sensitivity, color perception, or mild distortion may persist even after the fluid is fully gone. These residual changes are often related to temporary stress on the RPE and photoreceptor cells during the episode.
One of the most important things to understand about CSCR is its tendency to come back. About half of patients who have had CSCR will experience a recurrence at some point. Recurrences can happen months or years after the initial episode. Each episode carries the potential for additional damage to the macula. For this reason, retina specialists typically recommend ongoing monitoring even after the fluid has resolved, along with continued attention to avoiding known triggers like corticosteroid use and unmanaged stress.
Chronic CSCR requires closer monitoring and often active treatment. Prolonged fluid accumulation under the retina can lead to permanent thinning and damage to the RPE and the photoreceptor cells above it. Over time, this can result in lasting vision loss. Real-world data from patients treated with half-dose PDT showed a mean improvement in visual acuity along with a mean reduction in retinal thickness of 66 microns (Survey of Ophthalmology, 2021). Early treatment of chronic cases is important to minimize permanent structural changes to the retina.
Living With Central Serous Chorioretinopathy
Patients diagnosed with CSCR can take an active role in managing their condition. The most impactful step is avoiding corticosteroid medications whenever possible. Patients should inform all of their healthcare providers about their CSCR diagnosis so that alternative medications can be considered. Stress reduction strategies such as regular exercise, adequate sleep, mindfulness practices, and counseling may also help lower the risk of recurrence.
Retina specialists often recommend that patients with a history of CSCR monitor their vision regularly at home. One simple method is the Amsler grid test, a card with a grid pattern of straight lines. By looking at the grid with each eye separately, a patient can detect new distortion, blurriness, or missing areas that could indicate a recurrence of fluid buildup. Any new or worsening visual symptoms should prompt a visit to a retina specialist for evaluation.
Even after a single episode of CSCR resolves completely, periodic follow-up with a retina specialist is recommended. These visits typically include OCT imaging to check for subtle fluid that may not cause noticeable symptoms. Patients with chronic or recurrent CSCR may need more frequent visits. Long-term follow-up also helps detect complications such as choroidal neovascularization, which can be treated effectively when caught early.
When to See a Retina Specialist
Anyone experiencing new blurriness, distortion, or dimness in the center of their vision should see a retina specialist for a comprehensive evaluation. While CSCR is one possible cause, these symptoms can also be associated with other macular conditions. A thorough examination and imaging can determine the correct diagnosis and guide appropriate next steps.
Patients who have been previously diagnosed with CSCR should contact a retina specialist promptly if they notice symptoms returning. Early evaluation can confirm whether fluid has reaccumulated and help the specialist decide whether observation or active treatment is the best course of action. Waiting too long during a recurrence may increase the risk of permanent damage to the macula.
Certain symptoms can indicate a more serious retinal problem and require immediate attention. A sudden increase in floaters, flashes of light, a curtain or shadow moving across the vision, or sudden vision loss in one eye should be evaluated by a retina specialist or emergency room as soon as possible. These symptoms may indicate a retinal tear or detachment, which requires urgent treatment to protect vision.
Questions and Answers
Most cases of acute CSCR resolve without permanent vision loss. However, chronic or frequently recurring CSCR can lead to lasting damage to the retinal pigment epithelium and the photoreceptor cells in the macula. This damage may cause a permanent reduction in visual sharpness, contrast sensitivity, or color perception. Seeking care from a retina specialist early and following recommended treatment plans can help reduce the risk of permanent changes.
Corticosteroids in any form, including nasal allergy sprays, have been linked to triggering or worsening CSCR. Patients with a history of CSCR should discuss all medications, including over-the-counter products, with their retina specialist and prescribing physicians. In many cases, alternative non-steroidal treatments are available. Patients should not stop prescribed medications without first consulting their doctor.
CSCR and age-related macular degeneration, or AMD, both affect the macula, but they are distinct conditions. CSCR typically occurs in younger adults and is caused by fluid leaking from the choroid through the RPE. AMD occurs predominantly in older adults and involves different disease processes, including drusen deposits in dry AMD and abnormal blood vessel growth in wet AMD. The treatments, risk factors, and long-term outlooks for each condition are different. A retina specialist can distinguish between these conditions using imaging tests.
Stress management alone is unlikely to resolve an active episode of CSCR. However, because psychological stress can trigger the body to produce cortisol, which may contribute to choroidal leakage, reducing stress may lower the risk of recurrence. Strategies such as regular physical activity, adequate sleep, relaxation techniques, and professional support for anxiety or high-stress situations may be beneficial as part of an overall management plan.
The frequency of follow-up visits depends on whether the CSCR is acute, chronic, or recurrent. During an active episode, a retina specialist may schedule visits every four to six weeks to monitor fluid levels with OCT imaging. After the fluid resolves, visits may be spaced further apart, such as every three to six months for the first year, and then annually. Patients with chronic CSCR or those receiving treatment like photodynamic therapy may need more frequent monitoring. A retina specialist will create a personalized follow-up schedule based on each patient's situation.